GB2198639A - Injectable composition containing carbon and collagen - Google Patents
Injectable composition containing carbon and collagen Download PDFInfo
- Publication number
- GB2198639A GB2198639A GB08630300A GB8630300A GB2198639A GB 2198639 A GB2198639 A GB 2198639A GB 08630300 A GB08630300 A GB 08630300A GB 8630300 A GB8630300 A GB 8630300A GB 2198639 A GB2198639 A GB 2198639A
- Authority
- GB
- United Kingdom
- Prior art keywords
- tendons
- collagen
- suspension
- carbon fibres
- syringe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229910052799 carbon Inorganic materials 0.000 title claims abstract description 18
- 102000008186 Collagen Human genes 0.000 title claims abstract description 16
- 108010035532 Collagen Proteins 0.000 title claims abstract description 16
- 229920001436 collagen Polymers 0.000 title claims abstract description 16
- 239000007972 injectable composition Substances 0.000 title 1
- 210000002435 tendon Anatomy 0.000 claims abstract description 30
- 241000283086 Equidae Species 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 7
- 239000000835 fiber Substances 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 5
- 238000012423 maintenance Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000009413 insulation Methods 0.000 claims 1
- 230000035876 healing Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 241000777300 Congiopodidae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Damaged tendons, especially those of horses are treated with comminuted carbon fibres suspended in collagen.
Description
INJECTABLE SUBSTANCE AND PROCESS FOR ITS PRODUCTION
This invention relates to an injectable substance for use in the medical treatment of damaged tendons, in particular tendons of horses, as well as to a process for the production of this substance.
Until a few years ago the medical treatment of tendons damaged by tearing of tendon fibrils took place exclusively by use of externally acting means, perhaps by rubbing in of an ointment. Cauterization was used in the veterinary treatment of damaged tendons of horses. The healing success achieved could be described, at best, as modest; thus for example competition and race horses had to be taken out of training for long periods. The operative measures which have become very common in recent years consist of local incisions (tendon splitting), which should bring about a speedy healing, as a result of the better circulation of blood in the affected region which occurs post-operatively. After favourable assessment of this healing method, at first, it had however to be recognised that, in general, no better healing success is to be achieved as a result of splitting.Furthermore, recently, attempts have been made to achieve rapidly an improved stability of the damaged tendons by implantation of carbon fibres and/or tendon material removed from another part of the same body. It appeared however that this very expensive and cost intensive treatment method of operative implantation leads merely to a systematic growth of the repair cells of the body itself extensively in the longitudinal direction of the tendon. This, indeed, can shorten essentially the healing time, yet on the other hand, as the implants must be threaded through a longer piece of the tendon, it brings with it the great danger of new damage as well as a high risk of infection.
According to the present invention, there is provided an injectable substance for the medical treatment of damaged tendons, in particular tendons of horses, which comprises comminuted carbon fibres suspended in collagen appropriate to the species whose tendons are to be treated.
This invention provides an injectable substance, that is, a substance which can be introduced into the damaged tendon region without operative activity, to produce systematic growth in the damaged region from the aforementioned introduced material. At the same time, there is a reduction in the dangers of damage and infection.
The sturdiness of a damaged tendon, for example a tendon of a horse, can only be achieved by building up of the cell material of the body of the animal. If there is success in systematically setting in progress as described hereinbefore, the natural repair mechanism in accordance with the lengthwise development of the tendons, the healing time can be significantly shortened.
Should the substance according to the invention now be injected directly into the damaged area, then the comminuted carbon fibre particles become arranged on their own in the direction of the lengthwise development of the tendons. This is indeed so, as a consequence of the minimal movements of the tendons also taking place when limb immobilisation measures are adopted for setting the tendons at rest, including nutrition and support apparatus therefor. The chains of carbon fibre particles thus forming therefore fully correspond to the carbon fibres implanted at high cost and with great danger.The collagen used for the suspending of the comminuted carbon fibres of suitable size, is a collagen appropriate to the species being used, for example horse collagen, and serves for its part as local reservoir for the "repair column" being formed from fibroblasts, collagen fibres, binder webs and the like. Because one is concerned with homologous collagen, undesired anaphylactoidal or like incompatibility syndromes are excluded with finite probability with respect to safety.
The application of the substance according to the invention can take place by aseptically performable injection instead of the hitherto massive iatrogenic involvement which was necessary, and can be carried out simply and quickly.
This invention also provides a process for the preparation of an injectable substance for the medical treatment of damaged tendons, wherein comminuted carbon fibres are introduced into collagen appropriate to the species whose tendons are to be treated and are distributed in this, the suspension then obtained being subjected to a predetermined constant storage temperature for maintenance of a viscosity sufficiently low for it to remain injectable from a syringe. The carbon fibres used in the practice of this invention preferably have a diameter of about 0.01 mm and are comminuted to small fibre particles of a length of 0.2 to 1.0 mm. For stirring of the carbon fibre particles in the specific collagen to be suspended therein, it is possible to use mixing methods, perhaps with the aid of mixers, centrifuges or ultrasonic apparatus.To reduce gelation with storage, the suspension is preferably cooled to a temperature of up to 15 0C, more preferably 10 C, and maintained at such a temperature. What is particularly appropriate for preparative purposes is to introduce the substance into the cylinder of a once-through syringe with canule fixed to it and for this syringe then to be stored until immediately before use in a chilled box. A substance to be introduced into such a once-through syringe consists for example of 4 cc of collagen and 5 vol% of carbon fibre particles.
Clearly the invention is- not limited to the indicated embodiment. There are potentially numerous variants with respect to the numbers for amounts and dimensions without departing from the scope of the invention. Also it is not necessary with all collagen types for cooling to be carried out for maintenance of the low viscosity (injectability), although care should be taken that a constant storage temperature is maintained.
Claims (11)
1. Injectable substance for the medical treatment of damaged tendons, in particular tendons of horses, which comprises comminuted carbon fibres suspended in collagen appropriate to the species whose tendons are to be treated.
2. Injectable substance as claimed in claim 1, wherein the carbon fibres are in the form of particles which have a diameter of about 0.01 mm and a length of from 0.2 to 1.0 mm.
3. Injectable substance for the medical treatment of damaged tendons, substantially as described herein.
4. A process for the preparation of an injectable substance for the medical treatment of damaged tendons, wherein comminuted carbon fibres are introduced into collagen appropriate to the species whose tendons are to be treated and are distributed in this, the suspension then obtained being subjected to a predetermined constant storage temperature for maintenance of a viscosity sufficiently low for it to remain injectable from a syringe.
5. A process claimed in claim 4, wherein the carbon fibres are in the form of particles which have a diameter of about 0.01 mm and a length of from 0.2 to 1.0 mm.
6. A process as claimed in claim 4 or 5, wherein the carbon fibre particles are distributed in the collagen by stirring, centrifugation or use of ultrasonics.
7. A process as claimed in any one of claims 4 to 6, wherein storage of the suspension is carried out at up to 15 0C.
8. A process as claimed in claim 7, wherein storage of the suspension is carried out at about 10 C.
9. A process according to any one of claims 4 to 8, wherein the suspension is introduced into the cylinder of a once-through syringe with canule fixed thereto the syringe is introduced with the suspension located therein into a container with thermal insulation for maintaining the suspension at the desired storage temperature.
10. A process as claimed in claim 9, wherein the syringe is so filled as to contain 4 cc of collagen containing 5 vol% of carbon fibres.
11. A process for the preparation of an injectable substance for the medical treatment of damaged tendons, substantially as described herein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8630300A GB2198639B (en) | 1986-12-18 | 1986-12-18 | Injectable substance and process for its production |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8630300A GB2198639B (en) | 1986-12-18 | 1986-12-18 | Injectable substance and process for its production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB8630300D0 GB8630300D0 (en) | 1987-01-28 |
| GB2198639A true GB2198639A (en) | 1988-06-22 |
| GB2198639B GB2198639B (en) | 1990-10-17 |
Family
ID=10609239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8630300A Expired - Lifetime GB2198639B (en) | 1986-12-18 | 1986-12-18 | Injectable substance and process for its production |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2198639B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2159111C1 (en) * | 1999-08-02 | 2000-11-20 | Общество с ограниченной ответственностью "Новые медицинские технологии" | Face skin care composition |
| DE4329668C2 (en) * | 1993-09-02 | 2001-05-17 | Werner Pruegner | Use a sterile collagen solution for tendon injuries |
-
1986
- 1986-12-18 GB GB8630300A patent/GB2198639B/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4329668C2 (en) * | 1993-09-02 | 2001-05-17 | Werner Pruegner | Use a sterile collagen solution for tendon injuries |
| RU2159111C1 (en) * | 1999-08-02 | 2000-11-20 | Общество с ограниченной ответственностью "Новые медицинские технологии" | Face skin care composition |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2198639B (en) | 1990-10-17 |
| GB8630300D0 (en) | 1987-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3318774A (en) | Treatment of osseous and other tissue | |
| DE3918628C2 (en) | Process for the production of a cross-linked biopolymer based on collagen, implant from this biopolymer and process for the production of this implant | |
| US4279812A (en) | Process for preparing macromolecular biologically active collagen | |
| RU2104703C1 (en) | Method of preparing material for osteoplastics and material prepared by this method | |
| Heiple et al. | A comparative study of the healing process following different types of bone transplantation | |
| US5827217A (en) | Process and apparatus for harvesting tissue for processing tissue and process and apparatus for re-injecting processed tissue | |
| Dale et al. | Prognosis of epiphysial separation | |
| McIntyre | Afferent limb of the myotatic reflex arc | |
| US20230414830A1 (en) | High-Strength Collagen Sponge | |
| WO2000029484A1 (en) | Process for preparing high density mechanically resistant insoluble collagen material in pure and combined forms | |
| Li et al. | Acellular allogeneic nerve grafting combined with bone marrow mesenchymal stem cell transplantation for the repair of long-segment sciatic nerve defects: biomechanics and validation of mathematical models | |
| CN111183152A (en) | Method for producing collagen vitrified gel and its purified product, and collagen vitrified gel obtained by the method and its purified product | |
| Herold et al. | The effect of growth hormone on the healing of experimental bone defects | |
| GB2198639A (en) | Injectable composition containing carbon and collagen | |
| Lynn et al. | Therapeutic efficacy of adipose-derived stem cells versus bone marrow stromal cells for irradiated mandibular fracture repair | |
| Vaughan | The use of carbon fibre implants for the repair of Achilles tendon rupture in dogs | |
| CN115501393A (en) | Hydrogel for repairing nerve defects and preparation method and application thereof | |
| US8597317B2 (en) | Method for repair of articular cartilage defect and a device used therein | |
| CN109432500A (en) | A kind of preparation method and application of collagen membrane support | |
| Segundo et al. | Platelet‐rich plasma, hydroxyapatite, and chitosan in the bone and cartilaginous regeneration of femoral trochlea in rabbits: Clinical, radiographic, and Histomorphometric evaluations | |
| González-Quevedo et al. | Improving the regenerative microenvironment during tendon healing by using nanostructured fibrin/agarose-based hydrogels in a rat Achilles tendon injury model | |
| EP0347496B1 (en) | Method for treating material for implantation and implant | |
| Hidd et al. | Fibrin biopolymer sealant and aquatic exercise association for calcaneal tendon repair | |
| US20160089474A1 (en) | Collagen Sponge | |
| EP4512438A1 (en) | Tissue matrix decellularized in multiple stages, and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |